Protocol Ledger

NCT07726342 · Phase II · RECRUITING

SMP-656 for HER2-Positive Advanced Breast Cancer

Interventional Phase II clinical trial protocol NCT07726342 sponsored by Chengdu SciMount Pharmatech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-10 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07726342
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07726342
Protocol FieldVerified Registry Value
NCT IdentifierNCT07726342
Consolidated Lead SponsorChengdu SciMount Pharmatech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2026-08-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI